H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating on Caladrius Biosciences (CLBS) today and set a price target of $18.50. The company’s shares closed yesterday at $2.93, close to its 52-week low of $2.80.
Pantginis noted:
“Valuation and risks to price target achievement; only need a little to be potentially quite meaningful. We reiterate our Buy rating and $18.50 price target. Our valuation is based on our clinical net present value (NPV) model, which allows us to flex multiple assumptions affecting a drug’s potential commercial profile. As part of our valuation projections, we make the following assumptions, which we also believe provide additional levels of conservatism to our projections.”
According to TipRanks.com, Pantginis ‘ ranking currently consits of no stars on a 0-5 ranking scale, with an average return of -2.2% and a 37.0% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as Applied Genetic Technologies, Iovance Biotherapeutics Inc, and Checkpoint Therapeutics Inc.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Caladrius Biosciences with a $12.25 average price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $11.65 and a one-year low of $2.80. Currently, Caladrius Biosciences has an average volume of 33.23K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Caladrius Biosciences, Inc. is a biopharmaceutical company, which engages in developing products in cardiovascular and autoimmune disease that have the potential to restore the health of people with chronic illnesses. Its product pipeline includes CLBS12, CLBS14, and CLBS03.
